| Quantity: | |
|---|---|
C Clinically relevant – DHT-induced model mimics human AGA pathogenesis, with androgen-mediated hair follicle miniaturization and alopecia.
Quantifiable endpoints - body weight, percentage hair loss (image analysis), skin histopathology (H&E), and hair follicle count and size measurements.
Mechanistically driven —direct DHT-AR pathway activation recapitulates the hormonal basis of AGA.
Translational value – ideal for testing 5α-reductase inhibitors (finasteride, dutasteride), androgen receptor antagonists, and hair growth stimulators (minoxidil).
IND Ready Packet – Research can be conducted in accordance with GLP principles.
DHT-induced C57BL/6 androgenic alopecia model
• Efficacy testing of 5α-reductase inhibitors (finasteride, dutasteride), androgen receptor antagonists and hair growth stimulators (minoxidil, plant extracts, peptides)
• Target validation of androgen receptor signaling in hair follicles
• Biomarker discovery (DHT levels, androgen receptor expression, hair cycle markers)
• Mechanism of action (MOA) studies of hair growth compounds
• IND Pharmacology and Toxicology Studies for Hair Loss Treatment Drugs
scope | Specification |
Species/Strain | C57BL/6 mouse (male) |
induction method | Apply dihydrotestosterone (DHT) topically or intradermally to the skin of the back daily or multiple times per week for 2-4 weeks |
study time | 2-5 weeks (induction + treatment phase) |
critical endpoint | Body weight, percentage hair loss (image analysis), skin histopathology (H&E) and follicle count and size measurements, anagen/telogen ratio, optional: androgen receptor expression, serum DHT levels, Ki67 immunohistochemistry (proliferation) |
packet | Raw data, analysis reports, clinical photos, histology slides, image analysis files, bioinformatics (optional) |
Question: How does DHT induce androgenic alopecia in mice?
Answer: DHT binds to androgen receptors (AR) in dermal papilla cells, triggering signaling pathways that lead to hair follicle miniaturization, shortened anagen, and progressive hair loss. This mimics human AGA pathogenesis, whereby 5α-reductase converts testosterone to DHT in susceptible follicles.
Q: What are the main similarities to human AGA?
A: This model exhibits progressive hair loss, hair follicle miniaturization, reduced hair follicle density, and response to standard treatments (minoxidil, finasteride), very similar to human male pattern baldness.
Q: Can this model be used for IND support studies?
Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different doses of DHT, local versus systemic administration, combination with other drugs)?
Answer: Of course. Our scientific team tailors DHT dosing regimens, application methods and endpoint analyzes to your specific drug candidate.
